Discussion
Using a different time scale of disease duration, we conducted a new analysis of the ICARS progression rate in the longest longitudinal study of Dutch SCA3 cohort [
18]. Compared with the previous age-index prediction models, our duration-index models have some advantages and can yield unique valuable insights into disease progression: (1) it is appropriate to reflect the natural timescale of SCA3 because of the strong correlation between duration and clinical severity or progression [
17,
35,
36]; (2) it is more relevant because at baseline the population is constrained to be within the patients having already developed SCA3, while age as time scale can amplify the a priori dis-synchronization of disease process between patients; (3) it may be better suited to be used in future clinical trials since it is a predictor of outcomes and some interventions can be used at different disease stages; (4) it is also useful to investigate whether the rates of ICARS progression changed by duration.
The results showed that using duration as time scale, the piece-wise growth model provided much better fit to the ICARS progression trajectory than linear and quadratic growth model. The progression rates of ICARS varied during the long period of SCA3 patients. Trajectories of ICARS progression were characterized by nonlinear trend and could change with different stages. At early-stage, i.e., in the first 13 years of duration, ICARS progressed more slowly than in the following process after 13 years. Compared to the initial analysis results by Leotti et al. [
18], our findings provide novel insights on the progression of SCA3 from another new perspective. In SCA3, this is the first study to suggest the non-linear pattern of disease progression during the long disease duration by comparing multiple linear and nonlinear growth models.
Similar phenomena were also observed in a variety of polyQ diseases including SCA2 [
15,
37], SCA6 [
17,
38], and HD [
12,
39,
40], etc. For example, in SCA2, the disease progression rates, as measured by Scale for the Assessment and Rating of Ataxia (SARA) and Neurological Examination Score for Spinocerebellar Ataxias (NESSCA), were also not uniform during the disease process: early phases of disease duration were related to slower progressions [
15]. In SCA6, two studies suggested a similar non-linear pattern of decline on SARA and Inventory of Non-Ataxia Symptoms (INAS) [
17,
38]. As for HD, one study showed that the annual growth rate of chorea was greater in the earlier-stage than in the advanced stage [
39]. While the total motor score, assessed in the Unified Huntington’s Disease Rating Scale (UHDRS), exhibited a relatively faster rate of progression in patients at mid-stage than those at early and late stage [
12]. Our findings, together with these previous reports, suggested that the non-linear progression pattern of clinical scales was plausible and disease progression may not be at the same rate throughout its course.
It might reflect the true biological effect of these diseases. Data from other objective imaging studies were also consistent with this natural phenomenon. For instance, the rate of caudate atrophy was positively correlated with disease duration. It seemed to progress more slowly in pre-symptomatic and early HD patients [
41]. The MRI white matter-ventricle scores displayed similar nonlinear trajectories with clinical motor-cognitive scores across the disease span in HD, with a slow, nonlinear progression pattern over time in gray matter loss [
40]. Furthermore, the ventricular enlargement rates of HD, which reflect the extension of pathology to extra-striatal gray matter and white matter regions, also accelerated with the prolongation of disease duration [
13]. Except for the biological causes, scale limitations may also explain this non-linearity progression pattern of rating scales. Current clinical measures of disease severity and outcome are limited by the floor and ceiling effects and lack sensitivity to early signs and changes over time [
12,
15]. On the one hand, in polyQ disease, a large proportion of patients at early-stage have subtle and vague signs but were poorly detected by scales. This might be associated with the slower slope of progression rate in the early stage as shown by our results and other similar findings [
15]. On the other hand, disease severity may not coincide with relevant clinical scales. We postulated that the inability of related scales to assess the progression after a certain disease stage may contribute to explain the slowdown of chorea and total motor score in the late stage of HD as mentioned above [
12,
39]. Notably, our results showed that CAGexp repeat length and AOga might not be the causes for the different progression rates at different stages. Regardless of the mechanism behind it, the direct use of linear models during prospective longitudinal studies, without consideration of the differences in disease duration, may ignore the non-linear progression pattern.
Consistent with previous results of Leotti et al. [
18], we also confirmed that the
ATXN3 CAGexp repeat length significantly influenced the speeding ICARS progression. Unlike this study, we investigated the impact of gender on disease progression. The results indicated that gender was not a significant modifier of ICARS progression. Similarly, there was no significant trend of association between ICARS increase and gender in one previous SCA3 study [
42]. Furthermore, three studies found that gender had no significant effect on SARA progression in SCA3, as well as in other any SCA type, including SCA1, SCA2 and SCA6 [
6,
17,
43]. Also, gender could not influence the NESSCA progression of SCA3 patients [
44]. However, two studies showed that the rate of INAS progression in SCA3 depended on gender, with faster increase in female patients than male patients [
6,
17]. According to our results and those previous studies, it can be suggested that there were no consistent conclusions and consensus on whether gender had an effect on disease progression in SCAs patients. Various scales measuring clinical progression among studies might contribute these inconsistent findings. We suspected that gender may not affect the increase of ataxia symptoms measured by ICARS, SARA and NESSCA, but the non-ataxic signs in INAS. Also, different ethnic or population background and observation or follow-up period among these studies may account for the discrepancies.
Additionally, we focused on the impact of AOga rather than RAO on disease progression. It might be more convenient and easier to be popularized clinically, because: (1) a model fitting the relationship between AOga and CAGexp is not required to calculate RAO; (2) accurate prediction of AOga based on CAGexp is still a great challenge. Our results showed that all related
P values of the slopes for AOga were greater than 0.05 in all models with AOga as the only modifier or combining AOga and CAGexp together. Similar phenomena were also observed in related models combining RAO and CAGexp as co-modifiers. It suggested that AOga (also a proxy for age during follow-up in our study) and RAO could not directly influence the progression rate of ICARS even if combining with CAGexp, which was different from this previous study of Leotti et al. [
18].
Similarly, some SCA3 studies also did not found a significant effect of AOga on the progression of ataxia as measured by ICARS and SARA [
6,
17]. Whereas two studies demonstrated a correlation between AOga and the non-ataxia progression rate, which was assessed by NESSCA and inventory of non-ataxia signs (INAS) [
6,
44]. Thus, the relationship of AOga to the speeding of progression in SCA3 is still debated. Similar to the gender effect, we speculated that it may be explained by the fact that AOga might affect the progression of non-ataxia in NESSCA and INAS but not ataxia signs in ICARS and SARA [
22]. Whether there is a different influence pattern of AOga on the progression of non-ataxia or ataxia signs is worthy of further exploration. Additionally, the different time scales among studies might also help to explain these discrepancies.
Interestingly, AOga could improve the model performances and increase the effect size of CAGexp on the progression of ICARS. Similar to our study, two HD studies also used AO as a proxy for age at the time of examination and discovered consistent results. One study demonstrated that including AO increased the correlation between CAGexp and disease progression of multiple clinical rating scales by 69–159% [
22]. Another study showed that CAGexp was the predictive factor of institutionalization but only after controlling for AO [
23]. These findings may highlight the importance of aging process on the clinical progression of SCA3 as reported by previous studies [
24,
37]. For example, the relationship between CAGexp and clinical progression could be masked by the effects of aging [
37]. A significant correlation between CAGexp and progression was observed only after adjusting for age at baseline [
24]. And the inconsistent results about the relationship between CAGexp repeat length and progression may also be associated with aging effects adjustment [
22]. Thus, it can be inferred that the natural effects of aging associated with a later AOga adversely influenced the speed of disease progression mainly through interacting with CAGexp. The aging factors may affect functional capacity, balance abilities, motor skills, visual-perceptual abilities, and other measures typically used to quantify the severity of polyQ disease [
45‐
50].
Our piece-wise linear growth models could be widely utilized in not only scientific research but also clinical practice. In scientific research, our predictive models can be used in experimental design studies on modifiers of progression. We can statistically correct the average effects of the major two modifiers, i.e., ATXN3 CAGexp and AOga, thus identifying other new risk factors of progression. Besides, the predictive models are valuable for clinical trials to determine the potential efficacy of treatment. The progression prediction from our model could be employed in the baseline data analysis, essentially in the subject stratification. It is beneficial to eliminate or minimize the effects of these known predictors of progression before randomly assigning patients to different treatment branches. In clinical practice, although the current model cannot be used directly due to its not very good prediction accuracy at this stage, it can be further optimized to achieve good prediction performance with the future incorporation of more modifiers. At that time, in genetic counseling, such accurate prediction may help to assess disease progression, which is instructive for optimizing future medical plans. Meanwhile, it is also crucial for the clinical intervention by classifying low/high risk patients with predicted lower/higher progression rates or scores. Those patients in the advanced disease stage with faster progression, may also require more intensive treatment and care to delay the progression and improve their quality of life. Such individualized predictions are very useful for personalized medical management and cost-effectiveness of treatment.
This study has some limitations. We lacked other commonly used clinical assessments like SARA and objective imaging data, which prevented us from comprehensively assessing disease progression. However, the longest longitudinal study ensures better monitoring and evaluation of the trajectory of progression. We did not conduct an independent prospective study and only reanalyzed the data of Leotti et al. [
18], but our novel insights could still provide new clues for future research on the progression of SCA3 or other polyQ diseases.
In the future, clinical trials in polyQ disease should ensure that different treatment groups are appropriately balanced for these factors of progression, including disease duration, CAGexp repeat length, and AOga. An imbalance may lead to the group differences in the rate of progression being unduly attributed to treatment effects. Given that AOga (a proxy for aging process) also affect the progression rate in SCA3 by interacting with CAGexp as described in HD [
22,
24], we recommend to consider the effect of age or AOga to avoid spurious findings either in randomization process or in statistical analysis when examining the influences of CAGexp on progression. In fact, it may reduce sample size requirements and improve statistical power to detect treatment-induced effects. Meanwhile, future research needs to focus on the exploitation of other new modifiers to slow down the progression by targeting some new interventionable factors. As mentioned above, the acquisition and incorporation of more modifiers would contribute to further optimization of our models for more accurate predictions. Furthermore, external validations of the models in other independent SCA3 and other polyQ diseases are needed to test its adaptability, flexibility and extensibility. In addition, further transformation of our models into clinical applications will necessarily require rigorous clinical testing in large, multicenter, multi-racial/ethnic cohorts at different stages, as well as well-designed clinical assessments and neuroimaging examinations.
In conclusion, through reanalyzing the longest longitudinal study of SCA3, we offered novel insights on the disease progression using a different time scale and analysis strategies. For the first time, this present study demonstrated that the progression rate of ICARS scales was not uniform during the long duration in SCA3, varying according to the phases of disease. Different time scales may affect the results of the analysis and combining two or more times scales can provide new insights into disease progression. It has great implications for understanding the biological characteristics of disease progression in SCA3 and other polyQ diseases. In addition to ATXN3 CAGexp repeat length, AOga or aging process may also modulate the progression in SCA3 through interacting with CAGexp. In polyQ disease, future clinical trials should take these phenomena into account, which would be conducive to determine inclusion criteria, assess treatment effect, reduce sample size requirements and increase statistical power. Moreover, our piece-wise linear growth models could facilitate genetic counseling, identification of novel modifiers on progression, personalized clinical management, and clinical trials design.